[□=□ | □] | □
[lemma=□ | □] | □
[tag=□ | □] | □
Results were essentially unchanged when the Cox Proportional Hazards regression model was repeated ( a ) using 1 medication episode per patient ( n = 1028 ) , the one with which the patient was treated first , ( b ) using 1703 treatment episodes , including episodes where patients simultaneously initiated 2 or more treatment episodes , ( c ) using the time elapsed between medication initiation and patients ' enrollment in the study , as a proxy for potential " sponsor-related physician bias , " ( d ) using a medication gap > 14 days to assess robustness of the > 30-day medication gap used to signal medication discontinuation , and ( e ) using ITT analysis , with 2488 treatment episodes , thus not requiring initiators to have continued in the study for at least 1 year following medication initiation . For the main analysis , all treatment group comparisons were made using ( a ) Kaplan-Meier survival analysis ( log-rank test ) , ( b ) Cox Proportional Hazards regression model , and ( c ) propensity score-adjusted bootstrap resampling method with 1000 iterations . To further assess the robustness of the findings , sensitivity analyses were performed , including the use of ( a ) only 1 medication episode for each patient , the one with which the patient was treated first , and ( b ) all medication episodes , including those simultaneously initiated on more than 1 antipsychotic . The p values are calculated via the log-rank test . The disorders of other examined cases were stroke ( 2 ) , traumatic brain injury ( 1 ) , mental retardation ( 2 ) , and dementia ( 1 ) . The match of any one protein from the reference genome to the phylogenetic profile becomes optimized for that protein by automatic selection of the most favorable BLAST E-value cutoff .